Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Young women with breast cancer often overestimate both their chance of developing cancer in the other breast and how much removal of that breast is likely to protect them, a new U.S. study suggests.
Women age 40 or younger when diagnosed with early-stage, HER2-positive breast cancer do not have an increased risk of early recurrence due to age. They also are as likely as older women to benefit from treatment with trastuzumab, or Herceptin, according to a recent study.
NEW YORK (Reuters Health) - Although recommendations differ on when women should start getting screened for breast cancer, a new study suggests women in their 40s may benefit from yearly mammograms.
NEW YORK (Reuters Health) - How doctors describe a non-invasive type of breast lesion may affect how women choose to have the abnormal cells treated, a new survey suggests.
An analysis of data from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial showed that the older a woman is at diagnosis of hormone-sensitive breast cancer, the greater her chance of distant recurrence over time. Distant recurrence refers to cancer that has spread to a part of the body beyond the breast and regional lymph nodes.
The National Comprehensive Cancer Network (NCCN) issued new guidelines that help doctors focus on the post-treatment needs of individuals diagnosed with and treated for cancer.
Research presented at the 2013 Annual Meeting of the American Association for Cancer Research found that African-American women have worse breast cancer-specific survival rates than women of other racial or ethnic groups, no matter the tumor subtype.
Overweight and obese women who had surgery plus radiation therapy to treat breast cancer, and who had 12 or more lymph nodes removed, were more likely to develop lymphedema than women of normal weight, an analysis showed.
A study of about 7,000 women treated with tamoxifen for early-stage, ER+ breast cancer showed lower recurrence and mortality rates for those who took the medication for 10 years instead of 5 years. This research, which has not yet been published, reinforces the findings of the international ATLAS trial.
In a recent study, researchers found that most women diagnosed with breast cancer do not meet national physical activity guidelines in the 10 years after diagnosis.